questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Indolizine
Indolizidines
Alcaloïdes indoliques
Alcaloïdes formés par condensation de sécologanine et de tryptamine
Alcaloïdes de Vinca
Vinblastine
Vinblastine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Vinblastine
Cancer
Diagnostic médical
Tests de laboratoire
Imagerie médicale
Vinblastine
Symptômes
2
Effets secondaires
Vinblastine
Nausées
Douleur
Vinblastine
Effets indésirables
Prévention
2
Prévention du cancer
Vinblastine
Traitement
Effets secondaires
Vinblastine
Médicaments antiémétiques
Traitements
2
Lymphome
Cancer du poumon
Vinblastine
Administration intraveineuse
Vinblastine
Traitement du cancer
Complications
2
Complications
Vinblastine
Infections
Moelle osseuse
Vinblastine
Dépression médullaire
Facteurs de risque
2
Facteurs de risque
Vinblastine
Maladies cardiaques
Vinblastine
Pédiatrie
Traitement du cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vinblastine : Questions médicales les plus fréquentes",
"headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-10",
"dateModified": "2025-02-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vinblastine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca",
"url": "https://questionsmedicales.fr/mesh/D014748",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vinblastine",
"alternateName": "Vinblastine",
"code": {
"@type": "MedicalCode",
"code": "D014747",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Christine Chevreau",
"url": "https://questionsmedicales.fr/author/Christine%20Chevreau",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Oncopole, Toulouse, France."
}
},
{
"@type": "Person",
"name": "Stéphane Culine",
"url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr."
}
},
{
"@type": "Person",
"name": "Gwenaelle Gravis",
"url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France."
}
},
{
"@type": "Person",
"name": "Florence Joly",
"url": "https://questionsmedicales.fr/author/Florence%20Joly",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Differential biases in human-human versus human-robot interactions.",
"datePublished": "2022-08-19",
"url": "https://questionsmedicales.fr/article/35994948",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.apergo.2022.103858"
}
},
{
"@type": "ScholarlyArticle",
"name": "Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: human cells migrating in human brain.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37490233",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11060-023-04349-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Human",
"datePublished": "2022-09-23",
"url": "https://questionsmedicales.fr/article/36211956",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcimb.2022.997315"
}
},
{
"@type": "ScholarlyArticle",
"name": "Human",
"datePublished": "2023-05-04",
"url": "https://questionsmedicales.fr/article/37141412",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/oncotarget.28409"
}
},
{
"@type": "ScholarlyArticle",
"name": "Human",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35982909",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.7150/ijbs.70007"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
},
{
"@type": "ListItem",
"position": 10,
"name": "Vinblastine",
"item": "https://questionsmedicales.fr/mesh/D014747"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vinblastine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vinblastine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-01",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vinblastine",
"description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Humans#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vinblastine",
"description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Humans#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vinblastine",
"description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Humans#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vinblastine",
"description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Humans#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vinblastine",
"description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Humans#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vinblastine",
"description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Humans#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de vinblastine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de la vinblastine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux."
}
},
{
"@type": "Question",
"name": "La vinblastine provoque-t-elle des douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de la vinblastine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine."
}
},
{
"@type": "Question",
"name": "Dans quels types de cancer la vinblastine est-elle utilisée ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule."
}
},
{
"@type": "Question",
"name": "Comment la vinblastine est-elle administrée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la vinblastine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des infections, des saignements et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "La vinblastine peut-elle affecter la moelle osseuse ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets indésirables avec la vinblastine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Les enfants peuvent-ils prendre de la vinblastine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 04/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Publications dans "Vinblastine" :
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-07-30
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
British journal of haematology
2018-12-28
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
4 publications dans cette catégorie
Affiliations :
Department of Medicine, Oncopole, Toulouse, France.
Publications dans "Vinblastine" :
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
The Lancet. Oncology
2019-07-19
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, François Baclesse Cancer Center, Caen, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Pathology, René Huguenin Curie Institute, Saint Cloud, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
2 publications dans cette catégorie
Affiliations :
Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Massachusetts General Hospital Cancer Center, Boston, MA.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.
Publications dans "Vinblastine" :
The research on human-robot interactions indicates possible differences toward robot trust that do not exist in human-human interactions. Research on these differences has traditionally focused on per...
Glioblastoma (GBM) is an aggressive primary brain cancer. Lack of effective therapy is related to its highly invasive nature. GBM invasion has been studied with reductionist systems that do not fully ...
Non-tumor brain samples were obtained from patients undergoing surgery (n = 7). Organotypic brain slices were prepared, and green fluorescent protein (GFP)-labeled primary human GBM IDH-wild type cell...
After placement, cells migrated towards blood vessels; initially migrating with limited directionality, sending processes in different directions, and increasing their speed upon contact with the vess...
Human organotypic models can accurately study cell migration ex vivo. GBM IDH-wild type cells migrate toward the perivascular space in blood vessels and their migratory parameters change once they con...
We identified four flea-borne spotted fever cases caused by...
The human Lymphocyte antigen-6 (...
Pancreatic cancer (PC) is a devastating solid malignancy with a dismal prognosis. The treatment of metastatic PC is a current challenge for medical oncologists due to a lack of early detection, drug r...
The interaction among joints of the midtarsal complex and subtalar joint is important for locomotor function; however, its complexity poses substantial challenges in quantifying the joints' motions. W...
From industrial exoskeletons to implantable medical devices, robots that interact closely with people are poised to improve every aspect of our lives. Yet designing these systems is very challenging; ...
Inspired by foundational studies in classical and quantum physics, and by information retrieval studies in quantum information theory, we prove that the notions of 'energy' and 'entropy' can be consis...
Industry 4 (I4) was a revolutionary new stage for technological progress in manufacturing which promised a new level of interconnectedness between a diverse range of technologies. Sensors, as a point ...
Human sapoviruses (HuSaVs), like human noroviruses (HuNoV), belong to the...